Mr. Michael Frank reports

REVIVE THERAPEUTICS ENTERS INTO AGREEMENT WITH DEFENCE RESEARCH AND DEVELOPMENT CANADA FOR EVALUATING BUCILLAMINE FOR NERVE AGENT EXPOSURE

Revive Therapeutics Ltd. has entered into an agreement with Defence R&D Canada -- Suffield Research Centre (DRDC), an agency of the Canadian Department of National Defence, to evaluate bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1 2024.

DRDC is investigating pharmacological compounds that can mitigate nerve-agent-induced brain injury. Recent studies have shown that antioxidant compounds such as n-acetylcysteine (NAC) could be beneficial in limiting seizure activity and improving the anti-convulsant efficacy of GABA-mediating (gamma-aminobutyric acid) drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. If promising, further studies will be conducted to facilitate Health Canada approval for the use of bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.

"We are excited to work with the DRDC in evaluating bucillamine as a potential therapeutic for nerve agent exposure and validating the novel uses and formulations of bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks," said Michael Frank, chief executive officer of Revive.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the Food and Drug Administration such as emergency use authorization, orphan drug, fast-track and breakthrough therapy designations. Currently, the company is exploring the use of bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of psilocybin-based therapeutics through various programs.

We seek Safe Harbor.